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ABSTRACT
Acinetobacter spp is one of the most common causes of nosocomial infection, 
especially sepsis. A lot of antibiotics resistance happen related to Acinetobacter-
related sepsis treatment. This study aimed to evaluate the potential of 
meropenem and piperacillin-tazobactam combination against Acinetobacter 
spp in in vitro by using paper strip test. This was experimental study conducted 
in September to December 2015 at Departement of Microbiology, Faculty of 
Medicine, Public health, and Nursing, Universitas Gadjah Mada, Yogyakarta, 
Indonesia. Clinical isolates of Acinetobacter samples were obtained from 
collections of the Department of Microbiology. The data were analyzed 
using post-test analysis which was conducted by observation over 24 h after 
the paper strip test was applied in bacterial culture. The MIC value of the 
antibiotic combination was recorded based on observation. The result showed 
12 of 17 clinical isolates were synergistic potential (70.59%) and 5 others were 
indifferent potential (29.41%). Two of five clinical isolates that show indifferent 
potential were A. baumannii and all of the clinical isolates that show synergistic 
potential were Acinetobacter spp. It can be concluded that the combination of 
meropenem and piperacillin-tazobactam showed more synergistic dominantly 
than the single use of each of them. 
ABSTRAK
Acinetobacter spp adalah salah satu penyebab paling umum infeksi nosokomial, 
terutama sepsis. Banyak resistensi antibiotik terjadi terkait dengan 
pengobatan sepsis yang berhubungan dengan Acinetobacter. Penelitian ini 
bertujuan untuk mengkaji potensi kombinasi meropenem dan piperacillin-
tazobactam terhadap Acinetobacter spp in vitro dengan menggunakan uji strip 
kertas. Penelitian eksperimental ini dilakukan pada bulan September hingga 
Desember 2015 di Departemen Mikrobiologi, Fakultas Kedokteran, Kesehatan 
Masyarakat, dan Keperawatan, Universitas Gadjah Mada, Yogyakarta. 
Isolat klinis sampel Acinetobacter diperoleh dari koleksi milik Departemen 
Mikrobiologi tersebut. Data dianalisis menggunakan analisis post-test yang 
dilakukan setelah pengamatan selama 24 jam setelah uji strip kertas pada 
kultur bakteri. Selanjutnya nilai MIC kombinasi antibiotik ditetapkan. Hasil 
penelitian menunjukkan 12 dari 17 isolat klinis berpotensi sinergis (70,59%) 
dan 5 isolat tidak ada potensial (29,41%). Dua dari lima isolat klinis yang 
menunjukkan tidak potensi sinergis adalah A. baumannii dan semua isolat 
klinis yang menunjukkan potensi sinergis adalah Acinetobacter spp. Dapat 
disimpulkan bahwa kombinasi meropenem dan piperacillin-tazobactam 
menunjukkan lebih sinergis dominan daripada penggunaan tunggal masing-
masing.
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INTRODUCTION
Acinetobacter spp. is the second most 
commonly found cause of sepsis after P. 
aeruginosa and before Stenotrophomonas 
maltophilia. Among Acinetobacter spp., 
the most familiar species to cause sepsis 
is Acinetobacter baumannii.1 Sepsis itself 
requires systematic and comprehensive 
treatment. Before specific bacteria are 
identified as the cause, therapy of empiric 
antibiotics will be given to reduce the 
effect of the infection. However, not only 
have to identify the bacteria of the cause, 
but the treatment of sepsis should also 
consider the type of empiric antibiotics 
given as it should be specified according 
to the source of infection. Moreover, 
the sensitivity of the antibiotics should 
fit the possible resistance pattern. If 
those considerations are not taken into 
account, they will increase the resistance 
risk of infection-causing bacteria against 
given antibiotics.2
Initial treatment of empiric 
antibiotics, if given appropriately, 
will be able to reduce mortality rate, 
hospitalization duration, and health 
cost. On the contrary, the inappropriate 
treatment can cause multi-drugs 
resistance (MDR) and increase mortality 
rate.2 Bacteria resistance cases against 
antibiotics are often found during 
single antibiotic treatments. In India, 
the combination of two antibiotics of 
cephalosporin and aminoglycoside class 
is more effective to treat sepsis caused 
by Acinetobacter spp. compared to single 
antibiotics treatment.3  In one of the 
hospital in Indonesia, 25 out of 342 blood 
specimens or patient’s sputum that 
diagnosed as sepsis showed resistant 
of 14 antibiotics (>50%) and <50% for 9 
antibiotics. The antibiotics that used are 
penicillin, cephalosporine, carbapenem, 
quinolone, aminoglycoside, macrolide, 
glycopeptide, sulfonamide, polymyxin, 
and antituberculosis.2
Single antibiotics treatment 
using antibiotics of aminoglycoside, 
amikacin, carbapenem, and β-Lactam 
class is often chosen to treat sepsis. 
However, this type of treatment has not 
been able to reduce the prevalence of 
death by sepsis especially in children 
patients, also when MDR take place.4 
Antibiotics in carbapenem class that 
is commonly used to treat sepsis is 
meropenem. Meropenem is a specific 
medicine for infections that caused by 
bacteria, therefore cannot be used for 
infections caused by fungi or viruses. 
Besides antibiotics in carbapenem class, 
other commonly used antibiotics for 
infections caused by bacteria are those 
from penicillin class or combination of 
penicillin and β-lactamase inhibitor. 
This type of medicine, for example in 
the form of piperacillin-tazobactam, is 
known for its ability to treat the infection 
from both gram-positive and gram-
negative bacteria. However, piperacillin-
tazobactam is still reported to cause 
resistance effect in treatments of heavy 
infections.5
Single-use of tazobactam has 
lower antibacterial properties than a 
combination with β-lactam, especially 
for Staphylococcus aureus, Haemophilus 
influenzae, Neisseria gonorrhoeae, 
Escherichia coli, and Acinetobacter spp. 
Piperacillin-tazobactam is the most 
active combination of therapy against 
infections caused by the bacillus genus, 
both aerobic and anaerobic, gram-
negative bacteria. This combination 
does not affect the pharmacokinetics 
system of each other.6 Ninety percent 
of E. coli and Enterobacteriaceae 
infection are sensitive to piperacillin-
tazobactam. It also shows sensitivity 
up to 90-100% in Streptococcus or 
Staphylococcus infections. Although 
these antibiotics show lower potential 
than meropenem and imipenem to treat 
Enterobacteriaceae and Acinetobacter 
spp. Infection, its have higher potential 
for treating Pseudomonas aeruginosa 
infection.7
In various researches about 
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antibiotics combination test, some 
methods appear more often than the 
others, such as paper strip test, time kill 
assay, antibiotic susceptibility test, and 
checkerboard test. From those methods, 
paper strip test is characterized as a 
simpler method with shorter time.8 
In this study, we aimed to evaluate 
the potential of meropenem and 
piperacillin-tazobactam combination 
against Acinetobacter spp in in vitro by 
using paper strip test.
MATERIALS AND METHODS
MATERIALS
Apparatus used in this research 
were sterile cotton swabs, inoculating 
loops, 5 mL and 15 mL tubes, 
micropipettes, oxidase test strips, Petri 
plates, object glass, McFarland standard, 
ruler, ©Liofilchem® (Italy) test strips 
containing meropenem and piperacillin-
tazobactam, bacteria growth incubator, 
documenting camera, and Acinetobacter 
spp. clinical isolates. Meanwhile the 
media were brain hearth infusion (BHI) 
medium, MacConkey agar medium, and 
Mueller-Hinton agar medium.
Acinetobacter spp.
These bacteria belong to ubiquitous, 
free-living Gram negative saprophytic 
bacilli class. This type of bacteria is 
commonly found in soil, water, human 
skin, also home/hospital furniture 
such as mattresses or rubber coatings. 
Acinetobacter spp. also often find in 
human skin as its infection medium. 
Acinetobacter spp., especially A. 
baumannii has a higher resistance to 
the hospital environment compared to 
other bacteria. These bacteria can stand 
a minimum of 10 days in the hospital 
environment and dry places.9 Patients 
with the long-term stay or post-surgery 
condition, invasive procedure, or lack of 
maintenance in surrounding objects can 
trigger Acinetobacter infection, such as 
on curtains, mattresses, or door handles.
Paper strip test
Paper strip test belongs to the 
antimicrobial susceptibility test (AST), 
which is a method used to examine the 
sensitivity rate of an antibiotic against 
gram-positive and gram-negative 
bacteria. In doing so, this method uses 
minimum inhibitory concentration (MIC) 
value as the indicator with a quantitative 
evaluation technique.
Sample collection
Acinetobacter spp. and A. baumannii 
samples were obtained from the collection 
of the Microbiology department, Faculty 
of Medicine, Public Health, and Nursing, 
UGM, and stored in glycerol solution at 
-80oC.
Acinetobacter spp. growth process
Bacteria growth processes were 
started from 17 samples collection. 
Acinetobacter clinical isolate (isolated 
by semi-automatic Microbact® method) 
goes through an oxidase test to confirm 
that the bacteria is oxidase-negative, 
proven by the absence of purple color 
in the result. Using a heated inoculating 
loop, the clinical isolate is streaked upon 
MacConkey agar medium and incubated 
for 20-24 h at 35±2 oC.
Inoculum preparation
Acinetobacter samples which had 
growth on MacConkey agar medium 
were collected using the inoculating loop 
at separate colonies. It was diluted inside 
NaCl-contained tube to 10-8 CFU/mL. The 
tube was compared with McFarland 
standard solution 0.5 and adjusted until 
the turbidity is visually similar.
Antibiotic sensitivity test
A sterile cotton swab was inserted 
into the inoculum tube and then streaked 
on Mueller-Hinton agar medium evenly. 
After 10-15 sec, meropenem paper strip 
was picked up with heated anatomic 
tweezers and placed on the agar 
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medium. The same action was done 
with piperacillin-tazobactam paper 
strip. Mueller-Hinton agar mediums 
with paper strips on were covered and 
incubated at 37oC for 18-24 h to obtain 
the MIC value of each antibiotic.
Antibiotic synergy test using paper 
strip
Acinetobacter was streaked on 
another Mueller-Hinton agar medium 
using a sterile cotton swab after MIC 
value was obtained. After 10-15 sec, 
meropenem paper strip and piperacillin-
tazobactam paper strip were picked 
up with heated anatomic tweezers and 
placed on the agar medium with the 
intersection point each at MIC 2 µg/mL 
and 4 µg/mL, forming 90o in the center 
of Mueller-Hinton agar medium. The 
medium was covered and incubated at 
37oC for 18-24 h. The MIC value of the 
combined antibiotics was determined 
from the value of inhibitor zone 
intersection at the scale of the paper 
strip. After obtaining the MIC value, 
fractional inhibitory concentration 
(FIC) of the combined antibiotics was 
calculated (FICa+b).
10  The  FICa+b = FICa + 
FICb, where
 FICa = (MIC A combine B/MIC 
A) and FICb = (MIC B combine A/MIC B). 
If, FICa+b value  < 0.5  it was considered 
as synergistic effect, if  FICa+b  value 
between 0.5 – 1.0 it was considered as 
additive effect, if  FICa+b value >1.0 – 4.0 
it was considered as indifferent effect 
and if FICa+b value > 4.0 it was considered 
as antagonistic effect. FIC value is 
influenced by antibiotic diffusion level on 
Mueller-Hinton agar medium, bacteria 
colony suspension on Mueller-Hinton 
agar media, sensitiveness of the tested 
bacteria towards both meropenem and 
piperacillin-tazobactam, and bacteria 
growth level.
Data analysis
Obtained data were analyzed 
with a post-test analysis which was 
conducted 24 h after paper strips were 
put on bacteria culture medium. From 
the observation, MIC value of each 
antibiotics combination was recorded 
according to their sensitivity level.
RESULTS
Gram staining and fermentation 
from the existing supply of clinical 
isolates were done to identify the 
bacteria type. After the clinical isolates 
identified as Acinetobacter spp., the 
bacteria were re-cultured on MacConkey 
agar medium. Afterward, the MIC 
values of single antibiotics previously 
tested (meropenem and piperacillin-
tazobactam) against Acinetobacter spp. 
were determined based on the MIC value 
standard on performance standards for 
antimicrobial susceptibility testing-CLSI 
2014. The result is showed in TABLE 1.
TABLE 1. MIC value of meropenem and piperacillin-tazobactam 
monotherapy to Acinetobacter (CLSI, 2014)
 Antibiotic
Antimicrobial susceptibility
Sensitive Intermediate Resistant
Meropenem < 2 4 > 8
Piperacillin-tazobactam < 4 8 - 16 > 32
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After the sensitivity test on the 
combination of meropenem and 
piperacillin-tazobactam against 
Acinetobacter spp. was conducted, 
the result can be used to determine 
the potential of the combination of 
the antibiotics into the categories of 
synergistic, additive, indifferent, or 
antagonistic. 
According to the identification 
table of meropenem and piperacillin-
tazobactam combination MIC value 
against Acinetobacter spp. (TABLE 2) 
there were 12 synergistic bacteria isolates 
(70.59%) and 5 indifferent bacteria 
isolates (29.41%). Meropenem and 
piperacillin-tazobactam combination 
average MIC value that showed the 
potential of synergy was 0.13, while the 
average MIC value of isolates showing 
the potential of indifference was 2. This 
result is presented in FIGURE 1 and 2.
TABLE 2. The MIC value of meropenem and piperacillin-tazobactam to Acinetobacter 
spp. (Source: primary data)
Bacterial 
Code
MIC (Minimum Inhibitory Concentration)
FIC (Fractional Inhibitory Concentration)
Notes
Monotherapy Combination
Meropenem Piperacillin-tazobactam Meropenem
Piperacillin-
tazobactam Meropenem
Piperacillin-
tazobactam
Meropenam 
and Piperacillin-
tazobactam
A1 32 256 32 256 1 1 2 Indifferent
A2 2 4 0.38 0.016 0.19 0.004 0.194 Synergistic
A3 2 4 0.38 0.023 0.19 0.00575 0.19575 Synergistic
A4 32 256 32 256 1 1 2 Indifferent
A5 32 256 32 256 1 1 2 Indifferent
A6 2 4 0.25 0.016 0.125 0.004 0.129 Synergistic
A7 2 4 0.094 0.064 0.047 0.016 0.063 Synergistic
A8 2 4 0.38 0,.016 0.190 0.004 0.194 Synergistic
A9 32 256 32 256 1 1 2 Indifferent
A10 32 256 32 256 1 1 2 Indifferent
A11 2 4 0.25 0.125 0.125 0.03125 0.15625 Synergistic
A12 2 4 0.19 0.016 0.095 0.004 0.099 Synergistic
A13 2 4 0.19 0.016 0.095 0.004 0.099 Synergistic
A14 2 4 0.19 0.016 0.095 0.004 0.099 Synergistic
A15 2 4 0.19 0.016 0.095 0.004 0.099 Synergistic
A16 2 4 0.19 0.016 0.095 0.004 0.099 Synergistic
A17 2 4 0.19 0.125 0.095 0.03125 0.12625 Synergistic 
 
FIGURE. 1. Synergistic MIC result of meropenem and piperacillin-
tazobactam on A2 (left) and A3 (right) clinical isolates.
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FIGURE. 2. Indifferent MIC result of meropenem and piperacillin-
tazobactam on A9 (left) and A10 (right) clinical isolates.
The potential of indifference resulted 
from 5 clinical samples, 2 of them (40%) 
were A. baumannii (A1 and A9), the other 
3 (60%) were Acinetobacter spp (A4, A5, 
and A10). The 5 isolates showed the FIC 
value of meropenem and piperacillin-
tazobactam combination was 2. Based 
on the 2014 CLSI guideline, the FIC value 
belonged to the indifferent category. On 
the other hand, the 12 clinical isolates 
show the potential of synergy (A2, A3, 
A6, A7, A8, and A11-A17) identified as 
Acinetobacter spp. (100%). At the 12 
isolates, the FIC value of meropenem and 
piperacillin-tazobactam combination 
was <0.5 (average value= 0.13). Based 
on the 2014 CLSI guideline, the FIC value 
belonged to the synergistic category.
DISCUSSION
The measurement of single 
antibiotics (meropenem and piperacillin-
tazobactam) MIC value against A1 
clinical isolate showed resistance on 
both meropenem and piperacillin-
tazobactam. This consistent with study 
by Harris et al.11 who reported that the 
use of single antibiotics like meropenem 
or piperacillin-tazobactam produces in 
resistance and increases morbidity and 
mortality by 10-20%.
Resistance to both tests of single 
antibiotics occurs due to the pathogenic 
properties of Acinetobacter spp., which 
results in the β-lactamase excretion, 
PBP modification, and increase in 
β-lactam outer membrane permeability. 
Therefore, a single antibiotics therapy in 
the form of meropenem or piperacillin-
tazobactam will result in resistance when 
it used to treat infection by Acinetobacter 
spp.
Another characteristic of 
Acinetobacter may also cause resistance 
against a certain antibiotic by increasing 
its active efflux, mutating the target area 
of the therapy, even inactivating the 
antibiotic.12,13 Twelve out of 17 clinical 
bacteria isolates (70.59%) showed 
synergistic results to the combination 
of antibiotics, while the remaining 
five isolates showed indifferent results 
(29.41%). This also corresponded to 
research by Viswanathan et al.3 in India, 
that reported from 50% non-fermenter 
gram-positive bacteria having MDR 
characteristics, 30% of them are resistant 
to carbapenem class antibiotics. Dewi et 
al.14 reported that the use of meropenem 
starts to show ineffectiveness or 
resistance to several sepsis-causing 
gram-negative bacteria.
Synergistic potential of the 
antibiotics combination (FIGURE 1) 
shows evident symbiosis between those 
antibiotics in increasing bactericidal 
effect. In the case of meropenem and 
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piperacillin-tazobactam combination, 
the symbiosis works by blocking 
the formation of bacteria wall and 
restraining the synthesis of β-lactamase, 
then finally binding itself with the 
protein of the bacteria, thus preventing 
the bacteria to bind with its host. The 
synergistic potential of meropenem and 
piperacillin-tazobactam combination 
was shown by the existence of bacterial 
growth inhibitor zone intersection 
(MIC value <0.5). On the other hand, 
indifferent potential (FIGURE 2) 
does not show any change or benefit 
from the combination of meropenem 
and piperacillin-tazobactam. This 
demonstrated that the effects of using 
single and combine antibiotic usage 
are similar. The indifferent potential of 
meropenem and piperacillin-tazobactam 
combination was shown by the same 
MIC value of single antibiotic and 
combined antibiotic of 32 and 256. After 
combination, both antibiotic samples did 
not show any symbiosis, proven by the 
inexistence of bacterial growth inhibitor 
zone intersection.
From 5 clinical isolates having the 
potential of indifference, 2 of them are 
A. baumannii. This bacteria type has 
higher resistance in various conditions 
compared to other types of Acinetobacter.1 
Therefore, it is assumed that the resistant 
nature is the cause of indifferent 
results on meropenem and piperacillin-
tazobactam combination test. Moreover, 
Acinetobacter, especially A. baumannii, 
has serine carbapenemase enzyme with 
higher effect against β-lactam antibiotics, 
especially carbapenem. The active efflux 
pump in A. baumannii also takes part in 
the resistance by exerting β-lactam from 
its cell membrane.
Although both meropenem and 
piperacillin-tazobactam had resistance 
possibility in single-use sensitivity 
test, there were synergistic and 
indifferent potentials when the two 
antibiotics were combined. This may 
due to the interaction of the antibiotics. 
Meropenem is a bactericidal antibiotic 
that kills bacteria by breaking down 
bacterial cell walls, while piperacillin-
tazobactam is a bacteriostatic antibiotic 
that inhibits β-lactamase enzyme exerted 
by Acinetobacter. The bacteriostatic 
ability of piperacillin-tazobactam 
may be able to protect meropenem 
from the β-lactamase enzyme exerted 
by Acinetobacter, therefore creating 
synergistic potential. However, the 
interaction between bactericidal and 
bacteriostatic antibiotics may also cause 
a rather dominant antagonistic potential 
since bactericidal antibiotics work by 
killing bacteria cell and bacteriostatic 
works by inhibiting bacterial cell 
growth. Therefore, the occurring effect 
is indifferent instead of positive.15
In this research, the usage of paper 
strip test was proven to be easy, simple, 
and did not take a long time or special 
experts. White et al.8 reported that paper 
strip test method can be examined by both 
qualitative and quantitative techniques. 
Compared to other methods such as 
time kill assay, antibiotic susceptible 
test or checkerboard test, paper strip 
test method is simpler and faster. 
However, the concentration/suspension 
of bacteria needed in the test will highly 
affect the final result. In appropriate 
of bacteria concentration may result in 
false results, both positive and negative. 
Therefore, spectrophotometer is needed 
to accurately measure the bacteria 
concentration to conduct the test.
CONCLUSION
The combination of meropenem 
and piperacillin-tazobactam generates 
more dominant synergistic potential, 
compared to the single-use of meropenem 
only or piperacillin-tazobactam only.
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